Recruiting

Opportunistic Salpingectomy

Sponsor:

Memorial Sloan Kettering Cancer Center

Code:

NCT06312124

Conditions

Surgery

Eligibility Criteria

Sex: Female

Age: 45+

Healthy Volunteers: Accepted

Interventions

Educational Module

Salpingectomy

Study Details

Brief summary:

The purpose of this study is to find out how many participants are interested in a surgical preventive procedure after watching an educational video. Before and after watching the video, participants will complete questionnaires in the clinic.

Conditions

Surgery

Study ID

NCT06312124

Start date

Mar 8, 2024

Status verified date

Jun, 2026

Completion date

Mar 8, 2028

Anticipated

Primary completion date

Mar 8, 2028

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: Female

Age: 45+

Healthy Volunteers: Accepted

Inclusion Criteria:

Part I

  • Age ≥45 years
  • Scheduled visit with a nongynecologic surgeon
  • Female or assigned female at birth

Part II

  • Age ≥45 years
  • At least one in situ fallopian tube
  • No desire or plan to have children in the future
  • Average risk of developing ovarian cancer

° Note: Average risk patients are defined as patients with no known genetic risk factor for developing ovarian cancer. Patients who, after obtaining family history, are suspected to have a hereditary ovarian cancer syndrome but have not yet been tested, will be referred for genetic evaluation.
  • Planned nongynecologic, intraabdominal, or pelvic surgery
  • Deemed to be a suitable candidate by gynecologic surgeon and primary nongynecologic surgeon (for example, on the basis of surgical history and current malignancy status)
  • Approved and signed informed consent

Exclusion Criteria:

Part I

  • Not fluent in English or Spanish

° If there is a non-english or non-spanish speaking participant who is a strong candidate and meets all other criteria for Part 2, they are able to go directly onto Part 2 without completing Part 1. (Please see additional details in section 4.1 and 7.0.)
  • Known inherited ovarian cancer susceptibility

Part II

  • Personal history of a gynecologic malignancy
  • Carrier of a hereditary breast or ovarian cancer variant (e.g., BRCA1, BRCA2, BRIP1, PALB2, RAD51C, RAD51D, MLH1, MSH2, MSH6, PMS2)
  • Suspicious ovarian, fallopian tube, or uterine lesion on preoperative imaging
  • Previous bilateral salpingectomy or bilateral salpingo-oophorectomy
  • Presence of ESSURE, or other tubal-implanted birth control at the time of surgery
  • Current pregnancy
  • Emergent procedure or emergency procedure that has to be completed within 24 hours where clinical consent occurs in the inpatient setting or where the patient's immediate well-being is in danger or condition may be life threatening
  • Primary surgeon anticipates that OS will add significant time (>30-40min) to the planned procedure.
  • Inability to access the pelvis (ex., patient prone/lateral position) during the planned procedure.
  • Known history of pelvic fibrosis or significant adhesions.
  • Procedures with palliative intent only

Study Design

Enrollment

266 participants

Anticipated

Intervention Model

Sequential

Primary purpose

Prevention

Interventions and Outcome Measures

Arms

experimental: Participants scheduled for non-gynecologic abdominopelvic surgery

Participants will be aged ≥45 years, have at least 1 fallopian tube, will not desire or plan to have children in the future, and will be scheduled to undergo non-gynecologic abdominopelvic surgery.

Interventions

Educational Module

Part 1 consists of an education module with premodule and postmodule assessment questionnaires.

Salpingectomy

Part 2 consists of incorporating opportunistic salpingectomy /OS into non-gynecologic surgery

Primary outcome measure

  • Rate of Opportunistic Salpingectomy/OS after completion of educational module [ Time Frame: up to 2 years ]

Central Contacts and Locations

Central contacts

Kara Long Roche, MD

212-639-7043longrock@mskcc.org

Martin Weiser, MD

212-639-6698weiser1@mskcc.org

Locations

Johns Hopkins University (Data Collection Only)

Recruiting

Baltimore, Maryland, United States, 21287

Contacts

Rebecca Stone, MD

410-955-8240

Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)

Recruiting

Basking Ridge, New Jersey, United States, 07920

Contacts

Kara Long Roche, MD

646-608-3787

Memorial Sloan Kettering Monmouth (Limited protocol activities)

Recruiting

Middletown, New Jersey, United States, 07748

Contacts

Kara Long Roche, MD

646-608-3787

Memorial Sloan Kettering Bergen (Limited Protocol Activities)

Recruiting

Montvale, New Jersey, United States, 07645

Contacts

Kara Long Roche, MD

646-608-3787

Memorial Sloan Kettering Cancer Center @ Suffolk-Commack (Limited protocol activities)

Recruiting

Commack, New York, United States, 11725

Contacts

Kara Long Roche, MD

646-608-3787

Memorial Sloan Kettering Westchester (Limited Protocol Activities)

Recruiting

Harrison, New York, United States, 10604

Contacts

Kara Long Roche, MD

646-608-3787

Memorial Sloan Kettering Cancer Center (All Protocol Activities)

Recruiting

New York, New York, United States, 10065

Contacts

Kara Long Roche, MD

646-608-3787

Memorial Sloan Kettering Nassau (Limited Protocol Activities)

Recruiting

Uniondale, New York, United States, 11553

Contacts

Kara Long Roche, MD

646-608-3787

MD Anderson Cancer Center (Data Collection Only)

Recruiting

Houston, Texas, United States, 77030

Contacts

Larissa Meyer, MD

713-792-6161

More Information

Sponsor

Memorial Sloan Kettering Cancer Center

Last update posted

Jun 24, 2026

Last verified

Jun, 2026

Keywords

  • abdominal surgery
  • pelvic surgery
  • Opportunistic Salpingectomy
  • ovarian cancer prevention
  • 24-006
  • Memorial Sloan Kettering Cancer Center

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by Memorial Sloan Kettering Cancer Center on 2026-06-24.